$1.19
4.42%
Nasdaq, Nov 13, 03:59 pm EST. Closed.
ISIN
IL0011319527
Symbol
ENLV

Enlivex Therapeutics Ltd Stock price

$1.19
-2.37 66.56% 1M
-174.59 99.32% 6M
-167.58 99.29% YTD
-236.43 99.50% 1Y
-418.81 99.72% 3Y
-1,969.21 99.94% 5Y
-14,398.81 99.99% 10Y
-80,638.81 100.00% 20Y
Nasdaq, Closing price Fri, Nov 13 2026
-0.06 4.42%
ISIN
IL0011319527
Symbol
ENLV
Industry

Is Enlivex Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.8m
Enterprise Value
$-3.9m
Net debt
positive
Cash
$5.8m
Shares outstanding
15.8m
Valuation
P/E
0.0
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.4 | 0.3
P/B
0.0
Financial Health
Equity Ratio
83.2%
Return on Equity
63.9%
ROCE
-0.7%
ROIC
-485.3%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$1.8m | -
SBC as % of FCF
-
SBC Growth 1Y
-14.0%
Share Count Growth 1Y
901.9%
Shareholder Yield
-
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-14.7m
EBIT
$-15.0m
Net Income
$1.2b
Free Cash Flow | ex SBC
$-10.5m | $-12.3m
Growth
Revenue | estimate
- | -
EBITDA
2.1%
EBIT
3.5%
Net Income
8,331.4%
Free Cash Flow
20.1%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$151.5
FCF per Share
$-0.7
Short interest
1.5%
Employees
34
Rev per Employee
$0.0

Enlivex Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Enlivex Therapeutics Ltd forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Enlivex Therapeutics Ltd forecast:

Buy
86%
Hold
14%

Enlivex Therapeutics Ltd Events

Past Events
NOV
12
Q3 2026 Earnings Call
2 days ago

Financial data from Enlivex Therapeutics Ltd

Dec '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.80 5.80
18% 18%
-
- Research and Development Expense 9.20 9.20
13% 13%
-
-15 -15
2% 2%
-
- Depreciation and Amortization 0.33 0.33
40% 40%
-
EBIT (Operating Income) EBIT -15 -15
3% 3%
-
Net Profit 1,236 1,236
8,331% 8,331%
-

In millions USD.

Don't miss a Thing! We will send you all news about Enlivex Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enlivex Therapeutics Ltd Stock News

Neutral
GlobeNewsWire
●
12 days ago
In patients aged 64+: 79.2% of patients achieved a clinically meaningful response (reduced pain and improved knee function) in the Allocetra™ group vs. 47.6% in the placebo group at 12 months (p=0.027)1   Allocetra™ treatment benefit at 12 months was consistent with the response rates observed at 3 and 6 months, demonstrating a durable effect from a single treatment cycle The 12-month data will...
Neutral
GlobeNewsWire
●
17 days ago
•      135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe •      Topline six-month data expected by mid-2027 •      Phase 2b builds on positive three- and six-month Phase 1/2a data, which supported FDA Regenerative Medicine Advanced Therapy (RMAT...
Neutral
GlobeNewsWire
●
18 days ago
Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting notification dated October 26, 2026 (the “Delisting Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”), stating that the closing bid ...
More Enlivex Therapeutics Ltd News

Company Profile

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Head office Israel
CEO Dr. Hershkovitz
Employees 34
Founded 2012
Website www.enlivex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today